6-K/A
Amended Financial Statements Report $86.8 Million Cash and $8.9 Million Net Income for Six Months Ended June 30, 2026
6-K
NervGen Pharma Corp. Announces Non-Reliance on Previously Issued Financial Statements and Planned Restatement
6-K
NervGen Pharma Corp. Announces Change of Auditor from KPMG Canada to KPMG US
6-K
NervGen Pharma Corp. Reports Q2 2026 Financial Results
6-K
NervGen Pharma Corp. Enters into At-the-Market Sales Agreement
6-K
NervGen Pharma Corp. Announces Pricing of US$60 Million Public Offering
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercial...